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Abstract
Background: Attention-deficit hyperactivity disorder is an early-onset, clinically heterogenous disorder
of inattention, hyperactivity, and impulsiveness. The diagnosis and treatment of attention-deficit
hyperactivity disorder continues to raise controversy, and, there is also an increase in treatment options.
In this 6-week double blind, placebo controlled-trial, we assessed the effects of zinc plus methylphenidate
in the treatment of children with attention deficit hyperactivity disorder. To the best of our knowledge,
this study is the first double blind and placebo controlled clinical trial assessing the adjunctive role of zinc
in ADHD.
Methods: Our subjects were 44 outpatient children (26 boys and 18 girls) between the ages of 5–11
(mean ± SD was 7.88 ± 1.67) who clearly met the DSM IV diagnostic criteria for attention-deficit
hyperactivity disorder and they were randomized to methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/
day (with approximately 15 mg zinc element) (group 1) and methylphenidate 1 mg/kg/day + placebo
(sucrose 55 mg) (group 2) for a 6 week double blind clinical trial. The principal measure of the outcome
was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline,
14, 28 and 42 days after the medication started.
Results: The present study shows the Parent and Teacher Rating Scale scores improved with zinc sulfate
over this 6-week, double blind and placebo controlled trial. The behavior of the two treatments was not
homogeneous across the time. The difference between the two protocols was significant as indicated by
the effect on the group, the between-subjects factor (F = 4.15, d.f. = 1, P = 0.04; F = 4.50, d.f. = 1, P = 0.04
respectively). The difference between the two groups in the frequency of side effects was not significant.
Conclusions: This double-blind, placebo-controlled study demonstrated that zinc as a supplementary
medication might be beneficial in the treatment of children with attention-deficit hyperactivity disorder.
However, further investigations and different doses of zinc are required to replicate these findings in
children with ADHD.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is the
most common behavioral disorder of childhood and is
recognized as one of the most prevalent chronic health
conditions in school-aged children, affecting an estimated
3% to 5% [1,2]. The key features of ADHD include hyper-
activity, impulsiveness, and inattention [1,2]. Although its
etiology remains unknown, data from family genetic, twin
and adoption studies as well as segregation analysis sug-
gest a genetic origin for some forms of this disorder [1,2].
Successful management of ADHD relies heavily on the
accuracy of its diagnosis, as well as on individualized
treatment planning. According to guidelines, significant
diagnostic components include 1) using DSM IV criteria
[3] 2) collecting information about the child's symptoms
in more than one setting; and 3) looking for coexisting
conditions that may impede the diagnostic process or
complicate treatment planning [1,2]. Stimulants are the
most commonly used drug therapy in ADHD patients are
burdened with a less than favorable pharmacokinetic and
pharmacodynamic profile associated with their use [4-7].
In spite of the good response of many patients with
ADHD to stimulant drugs, a substantial percent do not
respond to or develop significant side effects from stimu-
lants [8,9]. For this reason, new investigations have been
initiated for ADHD treatment [10,11]. Deficiencies in cer-
tain vitamins and mineral have also been found to have
some correlation with ADHD [12-14].
Zinc is an essential cofactor over 100 enzymes, both met-
alloenzymes and metal-enzyme complexes, required in
the metabolism of carbohydrates, fatty acids, proteins,
and nucleic acids [12,13]. Past studies have suggested that
there may be a correlation of zinc deficiency and patho-
physiology of ADHD [12-14]. Melatonin is a hormone
that plays an important role in the regulation of
dopamine, thought to be a factor in ADHD [14]. Mela-
tonin is sold over the counter as dietary supplement and
has been proven helpful in regulating the sleep cycle of
children with ADHD. Zinc is involved in the production
and modulation of melatonin, and therefore is also con-
sidered to be a factor in ADHD [12-14]. In this 6-week
double blind, placebo controlled-trial, we assessed the
effects of zinc plus methylphenidate vs. methylphenidate
plus placebo in the treatment of children with attention
deficit hyperactivity disorder. To our knowledge, this
study is the first double blind and placebo controlled clin-
ical trial assessing the adjunctive role of zinc in the
ADHD.
Methods
Trial organization
This was a 6 week, parallel group, placebo controlled trial
undertaken in Roozbeh Psychiatric Hospital, Tehran, Iran
during January 2002–October 2003.
Participants
The subjects were 44 outpatient children (26 boys and 18
girls) between the ages of 5–11 (mean ± SD was 7.88 ±
1.67) who clearly met the DSM IV [3] diagnostic criteria
for ADHD, and who were recruited from the outpatient
child and adolescents clinic of Roozbeh Psychiatric Hos-
pital. The diagnosis of ADHD was confirmed by a child
and adolescent psychiatrist before participants were initi-
ated into the study. All patients had combined subtype of
ADHD and were newly diagnosed and had not received
another stimulant medication prior to enrollment. Par-
ents were carefully interviewed and asked to rate the sever-
ity of the DSM IV inattention symptoms their children
displayed. Children were excluded if they had been previ-
ously diagnosed with a psychiatric disorder or mental
retardation (I.Q. < 70). In addition, we excluded patients
if they had a clinically significant chronic medical condi-
tion, including a past history of cardiovascular disease,
organic brain disorder, seizures, current abuse or depend-
ence on drugs within 6 months and current treatment
with psychotropic medications. To participate, parents
and children had to be willing to comply with all require-
ments of the study. After a description of the procedures
and purpose of the study, written informed consent was
obtained from each patient's parent or guardian.
Informed consent (parent and children) was received
before the administration of any study procedure or dis-
pensing of study medication in accordance with the ethi-
cal standards of the investigative site's institutional review
board and with the Helsinki declaration of 1975, as
revised in 2000 [15].
Study design
Patients underwent a standard clinical assessment com-
prising a psychiatric evaluation, a structured diagnostic
interview and a medical history. Patients were rand-
omized to receive methylphenidate + zinc or methylphe-
nidate + placebo in a 1: 1 ratio using a computer-
generated code. The assignments were kept in sealed,
opaque envelopes until the point of allocation. The rand-
omization and allocation process was done by the phar-
macist of the Roozbeh hospital. All study subjects were
randomly assigned to receive treatment using either meth-
ylphenidate 1 mg/kg/day (bid, 7 AM and 3 PM) + zinc
sulfate 55 mg/day (with approximately 15 mg zinc ele-
ment) (group 1) and methylphenidate 1 mg/kg/day (bid,
Table 1: Baseline data
Zinc sulfate Group Placebo Group
Girl 81 0
Boy 14 12
Age (Mean ± SD) 8.04 ± 1.73 (year) 7.73 ± 1.63 (year)
Ethnicity All Persian All PersianBMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/9
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7 AM and 3 PM) + Placebo (sucrose 55 mg) (group 2) for
a 6 week double blind clinical trial. Throughout the study
the person who administrated the medications, rater and
patients were blind to assignments. The principal measure
of the outcome was the Teacher and Parent ADHD Rating
Scale [16] that has been used extensively in Iran in school-
age children, and provides valid measures of behavioral
abnormality and attention. A score of at least 20 on the
rating scales was required for entry into the study. Patients
were assessed by a child psychiatrist at baseline, 14, 28
and 42 days after the medication started. 4 patients
dropped out from the trial (two from each group), leaving
40 patients who completed the trial. Side effects were sys-
tematically recorded throughout the study and were
assessed using a checklist administered by a resident of
psychiatry on day 7, 14, 21, 28 and 42 (Table 2).
Statistical analyses
A two-way repeated measures analysis of variance (time-
treatment interaction) was used. The two groups as a
between-subjects factor (group) and the four measure-
ments during treatment as the within-subjects factor
(time) were considered. This was done for Teacher and
Parent ADHD Rating Scale scores. In addition, a one-way
repeated measures analysis of variance with a two-tailed
post-hoc Tukey mean comparison test were performed on
the change in Teacher and Parent ADHD Rating Scale
scores from baseline. Results are presented as mean ± SEM
differences and were considered significant with P = 0.05.
To compare the demographic data and frequency of side
effects between the protocols, Fisher's exact test (two
sided) was performed. A traditional "observed cases"
(OC, the patients who completed the trial) analysis at 6
weeks was the primary efficacy analysis. In addition,
intention to treat (ITT) analysis with the last observation
carried forward (LOCF) procedure was also performed.
All results discussed are based on OC analysis unless oth-
erwise stated. To consider, a = 0.05, β = 0.2, the final dif-
ference between the two groups at least score of 5 on the
Teacher and Parent ADHD Rating Scale, S = 5 and power
= 80%, the sample size was calculated at least 15 in each
group.
Results
No significant differences were identified between
patients randomly assigned to the group 1 or 2 conditions
with regard to basic demographic data including age, gen-
der and ethnicity (Table 1).
Parent ADHD rating scale
The mean ± SEM scores of two groups of patients are
shown in Fig. 1. There were no significant differences
between two groups at day 0 (baseline) on the Parent
ADHD Rating Scale (P = 0.86). Both groups showed a sig-
nificant improvement over the 6 weeks of treatment (P <
0.000) and the trend was linear. The difference between
the two treatments was significant as indicated by the
effect of group, the between-subjects factor (F = 4.15, d.f.
= 1, P = 0.048 & F = 4.27, d.f. = 1, P = 0.045 for OC and
LOCF analyses respectively). The behavior of the two
treatment groups was not homogeneous across the time
(groups-by-time interaction, P < 0.000). In another word,
the behavior of the two treatment groups changed across
the trial. In addition, a one-way repeated measures analy-
sis of variance showed a significant effect of both treat-
ments on the Parent ADHD Rating Scale scores. In both
groups post-hoc comparisons of the baseline the Parent
ADHD Rating Scale scores with the scores at day 42 by
means of the Tukey procedure revealed significant
decreases from baseline. The differences between the two
treatments were significant at the endpoint (P = 0.0009 &
P = 0.001 for OC and LOCF analyses respectively). A sig-
nificant difference was observed on the reduction of
scores of the Parent ADHD Rating Scale at week 6 com-
pared to baseline in the two groups (P = 0.0003 & P =
0.0001 for OC and LOCF analyses respectively).
Teacher ADHD rating scale
The mean ± SEM scores of the two groups are shown in
Fig. 2. No significant differences were observed at baseline
on the Teacher ADHD Rating Scale (P = 0.85). Both
groups showed a significant improvement over the 6
weeks of treatment (P < 0.000) and the trend was linear.
The difference between the two treatments was significant
as indicated by the effect of the group, the between-sub-
Table 2: Clinical complications and side effects were reported as number per group.
Side Effects Zinc sulfate Placebo P
Anxiety 33 N s
Decreased Appetite 87 N s
Difficulty Falling Sleep 66 N s
Abdominal Pain 8 4 0.31
Nausea 9 3 0.08
Headache 99 N s
Metallic taste 13 0 0.0001BMC Psychiatry 2004, 4 http://www.biomedcentral.com/1471-244X/4/9
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jects factor (F = 4.50, d.f. = 1, P = 0.04 & F = 4.58, d.f. = 1,
P = 0.038 for OC and LOCF analyses respectively). The
behavior of the two treatment groups was not
homogeneous across the time (groups-by-time interac-
tion; P < 0.000). In addition, a one-way repeated meas-
ures analysis of variance showed a significant effect of
both treatments on the Teacher ADHD Rating Scale
scores. In both groups post-hoc comparisons of the base-
line the Teacher ADHD Rating Scale scores with the scores
at day 42 by means of the Tukey procedure revealed signif-
icant decreases from baseline. The differences between the
two treatments were significant at the endpoint (P =
0.0009 & P = 0.001 for OC and LOCF analyses respec-
tively). A significant difference was observed on the reduc-
tion of scores of the Teacher ADHD Rating Scale at week 6
compared to baseline in the two groups (P= 0.0004 & P =
0.0005 for OC and LOCF analyses respectively).
Retention in treatment
In both groups the number of dropouts was 2 and this was
lost in the follow up. Therefore, no significant difference
was observed in the two groups.
Clinical complications and side effects
A number of probable side effects were studied (Table 2).
Nausea was observed more in the zinc sulfate group.
Mean ± SEM scores of two groups of children on the Parent ADHD Rating Scale Figure 1
Mean ± SEM scores of two groups of children on the Parent ADHD Rating Scale. ns = non-significant, *** = P < 0.001. The hor-
izontal symbols (***) were used to express statistical significance versus their respective baseline value and the vertical symbols 
are for between group comparisons.
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Discussion
The diagnosis and management of children with ADHD
remains a challenge [11]. In the last decade, several stud-
ies into the role of trace element in enlightening the aeti-
ology of ADHD had been conducted. Most notable
among the studies are the ones particularly examing the
relation between zinc and ADHD [12-14]. Indeed, zinc is
basic for the production and modulation of melatonin,
which helps regulate dopamine function, supposed to be
an important factor in ADHD and its treatment [14].
Therefore, ADHD children with zinc deficiency might
benefit from a change in diet or from a therapeutic trial
with zinc supplementation. The present study shows the
Parent and Teacher Rating Scale scores improved with
zinc sulfate over this 6-week, double blind and placebo
controlled trial. The efficacy of zinc sulfate to obtain a bet-
ter improvement in children with ADHD seems to sup-
port the role of zinc deficiency in the etiopathogenesis of
ADHD [12,13]. The present study is in line with the recent
trial that suggests a beneficial effect of zinc sulfate in the
treatment of ADHD [17]. However, the present study
assessed the adjunctive role of zinc in the ADHD for the
first time. No significant differences were observed in the
rates and reasons for discontinuation in treatment in the
zinc and placebo groups. This finding suggested that tol-
erability of zinc and placebo was similar. Nausea was
observed more in the zinc group but did not differ signif-
icantly between the two groups (P = 0.08). In addition,
Mean ± SEM scores of two groups of children on the Teacher ADHD Rating Scale Figure 2
Mean ± SEM scores of two groups of children on the Teacher ADHD Rating Scale. ns = non-significant, *** = P < 0.001. The 
horizontal symbols (***) were used to express statistical significance versus their respective baseline value and the vertical sym-
bols are for between group comparisons.
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the metallic taste of zinc was complained of by the major-
ity of cases in the zinc group (13 out of 22). The limita-
tions of the present study, including lack of a full placebo
group, using only a moderate dose of methylphenidate,
the small number of participants, short period of follow
up and lack of plasma zinc concentration should be con-
sidered so further research in this area is needed. How-
ever, a study from the Middle East region has reported that
there may be a correlation of zinc deficiency and patho-
physiology of ADHD [13] and suggests that the treatment
of zinc in ADHD would be more beneficial in cases that
have low zinc levels. In conclusion, this double-blind,
placebo-controlled study demonstrated that zinc as a sup-
plementary medication might be beneficial in the treat-
ment of children with ADHD. However, further
investigations and different doses of zinc are required to
replicate these findings in children with ADHD.
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